Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To differentiate effects of lovastatin on low density lipoprotein (LDL) receptor activity from effects on LDL metabolic properties, LDL apolipoprotein B (apoB) turnover was studied in eight hyperlipidemic subjects during baseline and lovastatin treatment, in the latter case with LDL tracers isolated during both baseline (C-LDL) and drug treatment (Rx-LDL) conditions. Lovastatin (40 mg/day) significantly lowered total plasma and LDL cholesterol levels (27% and 25%, respectively) as well as plasma triglyceride levels (30%). Using contemporaneous tracers (C-LDL before and Rx-LDL during treatment), lovastatin caused a modest increase in LDL fractional catabolic rate (FCR) (0.410 ± 0.113 vs. 0.339 ± 0.108 pools/day, P < 0.04 by paired t ). The increase in LDL tracer FCR was higher when C-LDL tracer isolated during the untreated period was injected during lovastatin treatment (0.496 ± 0.177 vs. 0.339 ± 0.108 pools/day, P < 0.02). These in vivo studies in humans were confirmed by injecting LDL tracers from two patients into five guinea pigs. The C-LDL tracer was cleared consistently faster than the Rx-LDL tracer (0.082 ± 0.018 vs. 0.057 ± 0.015 pools/h, P < 0.001). The results demonstrate three important outcomes of lovastatin treatment in these subjects: LDL receptor activity increased by 49% ( P < 0.02); LDL apoB production rate decreased by 17% ( P < 0.03), and LDL particle in vivo affinity for the LDL receptor decreased by 15% ( P < 0.01). The decrease in LDL particle affinity partially negated the expected effect of increased LDL receptors on LDL clearance. The present study provides an explanation for earlier observations by several investigators using contemporaneous tracers that treatment with HMG-CoA reductase inhibitors resulted in only modest increases in low density lipoprotein functional catabolic rate. —Berglund, L., J. L. Witztum, N. F. Galeano, A. S. Khouw, H. N. Ginsberg, and R. Ramakrishnan. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J. Lipid Res. 1998. 39: 913–924.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.
Brown, M. S., & Goldstein, J. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111044 · Cited by 545
Lipoprotein-receptor interactions
Innerarity, T. L., Pitas, R. E., & Mahley, R. W. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29091-6 · Cited by 186
Cited by
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 396
Critical review of acylation-stimulating protein physiology in humans and rodents
Cianflone, K., Xia, Z., & Chen, L. Y. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00686-7 · Cited by 364
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240
Self-citationNagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Self-citationForster, L. F., Stewart, G., Bedford, D., Stewart, J. P., Rogers, E., Shepherd, J., Packard, C. J., & Caslake, M. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00052-7 · Cited by 77
Metadata
- Authors
- Berglund, L., Witztum, J. L., Galeano, N. F., Khouw, A. S., Ginsberg, H. N., & Ramakrishnan, R.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1998-04
- Volume
- 39
- Issue
- 4
- Pages
- 913-924
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2109741073
- Cited by
- 36
- References
- 3
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. https://app.cochat.ai/papers/10.1016/s0022-2275(20)32577-3
- The paper
- Berglund, L., Witztum, J. L., Galeano, N. F., Khouw, A. S., Ginsberg, H. N., & Ramakrishnan, R. (1998). Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. Journal of Lipid Research. https://doi.org/10.1016/s0022-2275(20)32577-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.